CordenPharma increases sterile injectable filling capacity to 500 million units annually
CordenPharma is investing €80 million in a new facility and expanded filling and finishing lines, aiming to boost sterile injectable production capacity to 500 million units per year.
CordenPharma, a contract development and manufacturing organization (CDMO), is significantly expanding its production capacity for sterile injectable drugs.
The company is investing €80 million in a new facility and additional aseptic filling and finishing lines. This expansion is expected to increase the annual capacity to 500 million sterile injectable units, catering to a growing demand in the pharmaceutical sector.
The investment aims to meet the increasing global demand for sterile injectable medications. As a CDMO, CordenPharma provides manufacturing services to other pharmaceutical companies, and this expansion will enhance its ability to serve a broader client base.
This move follows previous announcements by CordenPharma regarding the expansion of its high-potency active pharmaceutical ingredient (HPAPI) capabilities. The focus on sterile injectables further solidifies the company's strategic growth in specialized pharmaceutical manufacturing.
The new capacity is anticipated to be operational over the next few years, reinforcing CordenPharma's role as a key supplier in the injectable drug market.